2013 Documentation Pharmaceutical Companies 
Express Pharma
MARCH 16, 2025
In India, pharmaceutical companies responded to global environmental concerns and government mandates by adopting greener manufacturing techniques. Indian companies will need to enhance their quality control mechanisms, data management systems, and documentation practices to comply with these demanding standards.
European Pharmaceutical Review
JULY 5, 2023
Having been originally published in 2007, then revised in 2013, this latest 2023 edition addresses evolving standards and container types. According the PDA, the standardised quality criteria in TR 43 are intended as a guidance overview for container manufacturers and for incoming container acceptance inspection at pharmaceutical companies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 23, 2021
The possibility of data being shared with third-parties including academic researchers and pharmaceutical companies raised concerns about whether the public is aware that they stand to lose control of private information on their physical, mental and sexual health. Now that’s been set back indefinitely. survey conducted in July.
European Pharmaceutical Review
SEPTEMBER 22, 2022
Dr Maier has over 25 years of experience in drug development and commercialisation at pharmaceutical companies in Europe, Canada, the United States and Asia. 2013 Oct; 48(10): 943–953. Published online 2013 Jul 2. Mayer-Hamblett N, Rosenfeld M, Treggiari MM et al. Pediatr Pulmonol. doi: 1002/ppul.22693. Thompson, LA.
pharmaphorum
MAY 14, 2021
Practically though, there are risks of additional processes and requirements (and expense) for pharmaceutical companies. It is also possible that companies may prefer to enter the EU market through the EMA process and avoid additional processes involving the MHRA and NICE.
Pharmaceutical Technology
OCTOBER 5, 2022
These, along with other similar claims, meant Biogen owed potential damages of $1,036,900,151 to the US and the various States, as per court documents. Ferry describes a popular solution among pharmaceutical companies. The $900 million dollar settlement was previously announced in June but has only been finalized this month.
European Pharmaceutical Review
FEBRUARY 1, 2024
In this Q&A, he explores the trends and challenges within the cardiovascular treatment space, as well as clinical development of the company’s lead candidate obicetrapib, a cholesterol ester transfer protein (CETP) inhibitor for lowering low-density lipoprotein-cholesterol (LDL-C) and ultimately reducing cardiovascular risk.
Expert insights. Personalized for you.
110 
Let's personalize your content